Platform Case Study I – Novel Allosteric Modulators of a7 nACh Receptor
Janssen wanted to identify novel modulators of the a7 nicotinic acetylcholine receptor, with the ultimate aim to develop novel CNS therapeutics for patients in need.
The identification of novel small molecules that modulate the activity of their target protein through allosteric binding sites is a known significant challenge
Beactica’s team of highly skilled scientists applied the Company’s SPR biosensor-based discovery platform with an experimental approach designed to identify allosteric modulators
Multiple novel small molecule modulators acting on previously unexplored allosteric binding sites were identified and confirmed to be physiologically active
The therapeutic programme was reprioritized by Janssen and the collaborative work was published in PNAS in May 2015
Spurny R, Debaveye S, Farinha A, Veys K, Vos A.M, Gossas T, Atack J, Bertrand S, Danielson UH, Tresadern G, Ulens C. (2015) Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor, PNAS, 112:E2543–52.